Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice

Round robin test on quantification of amyloid-β 1–42 in cerebrospinal fluid by mass spectrometry

(2016) Josef Pannee et al.   Alzheimers & Dementia

Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis

(2016) Lucilla Parnetti et al.   Biomarkers in Medicine

Synaptic failure and α-synuclein

(2016) Laura Calo et al.   MOVEMENT DISORDERS

Increased CSF neurogranin concentration is specific to Alzheimer disease

(2016) Henrietta Wellington et al.   NEUROLOGY

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

(2015) Hlin Kvartsberg et al.   Alzheimers & Dementia

Non-motor signs in Parkinson’s disease: a review

(2015) Renato P. Munhoz et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders

(2015) Zheng-Yu Wang et al.   INTERNATIONAL PSYCHOGERIATRICS

A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

(2015) N K Magdalinou et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies

(2015) Davide Chiasserini et al.   Molecular Neurodegeneration

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

(2015) Niels Kruse et al.   NEUROBIOLOGY OF AGING

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

(2015) Sebastian Palmqvist et al.   NEUROLOGY

Amyloid biomarkers in Alzheimer's disease

(2015) Kaj Blennow et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

(2015) Julien Dumurgier et al.   Alzheimers Research & Therapy

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

(2015) Tessandra Stewart et al.   Acta Neuropathologica Communications

Increased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels

(2014) Sylvie Slaets et al.   Alzheimers & Dementia

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease

(2014) Karen E. Murphy et al.   BRAIN

Mass Spectrometry-Based Candidate Reference Measurement Procedure for Quantification of Amyloid-  in Cerebrospinal Fluid

(2014) A. Leinenbach et al.   CLINICAL CHEMISTRY

Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease

(2014) Hortensia Alonso-Navarro et al.   CURRENT DRUG METABOLISM

Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies

(2014) Stephen N. Gomperts   Current Neurology and Neuroscience Reports

Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

(2014) Takashi Kasai et al.   JOURNAL OF NEUROLOGY

Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease

(2014) Yaroslau Compta et al.   JOURNAL OF NEUROLOGY

Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions

(2014) Nadia Magdalinou et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A Sensitive A  Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid

(2014) M. J. Savage et al.   JOURNAL OF NEUROSCIENCE

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease

(2014) Lucilla Parnetti et al.   MOVEMENT DISORDERS

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

(2014) Alberto Lleó et al.   Nature Reviews Neurology

CSF biomarkers and clinical progression of Parkinson disease

(2014) S. Hall et al.   NEUROLOGY

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

(2014) Oskar Hansson et al.   Alzheimers Research & Therapy

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers

(2014) Jan O. Aasly et al.   Frontiers in Aging Neuroscience

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

(2014) Lucilla Parnetti et al.   Frontiers in Aging Neuroscience

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42

(2014) Sebastian Palmqvist et al.   JAMA Neurology

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

(2014) Niklas Mattsson et al.   Annals of Clinical and Translational Neurology

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration

(2013) Carole S. Scherling et al.   ANNALS OF NEUROLOGY

Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies

(2013) Adrien W. Schmid et al.   MOLECULAR & CELLULAR PROTEOMICS

Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease

(2013) Karin D. van Dijk et al.   MOVEMENT DISORDERS

The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease

(2013) Z. Gan-Or et al.   NEUROLOGY

CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls

(2013) Megan K. Herbert et al.   PARKINSONISM & RELATED DISORDERS

Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy

(2013) Malin Wennström et al.   PLoS One

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease

(2013) Mikko Hölttä et al.   PLoS One

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples

(2013) Tobias Skillbäck et al.   Alzheimers Research & Therapy

Correlation of Specific Amyloid-β Oligomers With Tau in Cerebrospinal Fluid From Cognitively Normal Older Adults

(2013) Maureen Handoko et al.   JAMA Neurology

Comparison of International Working Group criteria and National Institute on Aging–Alzheimer’s Association criteria for Alzheimer’s disease

(2012) Pieter Jelle Visser et al.   Alzheimers & Dementia

Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium

(2012) Maria C. Carrillo et al.   Alzheimers & Dementia

Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue

(2012) Kim A. Bruggink et al.   ANALYTICAL BIOCHEMISTRY

Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains

(2012) Matthew E. Gegg et al.   ANNALS OF NEUROLOGY

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

(2012) Sara Hall et al.   ARCHIVES OF NEUROLOGY

Clinical Chemistry and Laboratory Medicine: an appreciation

(2012) Graham H. Beastall et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression

(2012) R. Tortelli et al.   EUROPEAN JOURNAL OF NEUROLOGY

iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia

(2012) Stefan Lehnert et al.   EXPERIMENTAL NEUROLOGY

Recent Advances in α-Synuclein Functions, Advanced Glycation, and Toxicity: Implications for Parkinson’s Disease

(2012) Erika Guerrero et al.   MOLECULAR NEUROBIOLOGY

Molecular machines governing exocytosis of synaptic vesicles

(2012) Reinhard Jahn et al.   NATURE

Injury markers predict time to dementia in subjects with MCI and amyloid pathology

(2012) I. A. van Rossum et al.   NEUROLOGY

Age and diagnostic performance of Alzheimer disease CSF biomarkers

(2012) N. Mattsson et al.   NEUROLOGY

Synaptic changes in Alzheimer’s disease and its models

(2012) J. Pozueta et al.   NEUROSCIENCE

Phosphorylated  -Synuclein in Parkinson's Disease

(2012) Y. Wang et al.   Science Translational Medicine

Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease

(2011) Fuyuki Tateno et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

(2011) Niklas Mattsson et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies

(2011) Joseph R. Mazzulli et al.   CELL

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

(2011) Brit Mollenhauer et al.   LANCET NEUROLOGY

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

(2011) Lucilla Parnetti et al.   MOVEMENT DISORDERS

Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts

(2011) Kurt A. Jellinger   MOVEMENT DISORDERS

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

(2011) Tim Bartels et al.   NATURE

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

(2011) William E. Klunk   NEUROBIOLOGY OF AGING

Soluble amyloid  -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

(2011) M. Jin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders

(2010) Ozlem Goker-Alpan et al.   ACTA NEUROPATHOLOGICA

The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia

(2010) Walter J. Schulz-Schaeffer   ACTA NEUROPATHOLOGICA

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

(2010) Min Shi et al.   ANNALS OF NEUROLOGY

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

(2010) Zhen Hong et al.   BRAIN

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

(2010) Annika Thorsell et al.   BRAIN RESEARCH

High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

(2010) Hiroaki Fukumoto et al.   FASEB JOURNAL

A novel, high-efficiency cellular model of fibrillar α-synuclein inclusions and the examination of mutations that inhibit amyloid formation

(2010) Elisa A. Waxman et al.   JOURNAL OF NEUROCHEMISTRY

CSF amyloid-  and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study

(2010) G. Alves et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Biomarkers in Alzheimer's disease drug development

(2010) Kaj Blennow   NATURE MEDICINE

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Detection of elevated levels of  -synuclein oligomers in CSF from patients with Parkinson disease

(2010) T. Tokuda et al.   NEUROLOGY

CSF amyloid   1-42 predicts cognitive decline in Parkinson disease

(2010) A. Siderowf et al.   NEUROLOGY

Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease

(2010) James B. Leverenz et al.   PARKINSONISM & RELATED DISORDERS

Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease

(2010) Carol Man Gao et al.   PLoS One

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type

(2009) Barbara J. Snider et al.   ARCHIVES OF NEUROLOGY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

(2009) Pieter Jelle Visser et al.   LANCET NEUROLOGY

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease

(2009) Yaroslau Compta et al.   MOVEMENT DISORDERS

Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies

(2009) L. Parnetti et al.   NEUROBIOLOGY OF DISEASE

Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients

(2009) Yoshiro Saito et al.   NEUROSCIENCE LETTERS

Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders

(2009) Radu Constantinescu et al.   PARKINSONISM & RELATED DISORDERS

Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance

(2008) Laura Parkkinen et al.   ACTA NEUROPATHOLOGICA

Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies

(2008) Lucilla Parnetti et al.   BIOLOGICAL PSYCHIATRY

The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease

(2008) T. Pan et al.   BRAIN

Amyloid   Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

(2008) I. Klyubin et al.   JOURNAL OF NEUROSCIENCE

Phenotype, diagnosis, and treatment of Gaucher's disease

(2008) Gregory A Grabowski   LANCET

Neuropathological Aspects of Alzheimer Disease, Parkinson Disease and Frontotemporal Dementia

(2008) Kurt A. Jellinger   Neurodegenerative Diseases

Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

(2008) Annika Öhrfelt et al.   NEUROSCIENCE LETTERS

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment

(2007) Miroslaw Brys et al.   NEUROBIOLOGY OF AGING